Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PANCREAS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23Linked to original sources
PubMed2005

Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.

Treatment of cultured PANC-1, MIA PaCa-2, and BxPC-3 human pancreatic adenocarcinoma cells with 0.1 to 1.6 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) for 96 h inhibited the proliferation of these cells in a dose-dependent manner, and PANC-1 and MIA PaCa-2 cells were more sensitive to TPA than BxPC-3 cells. Inhibition of proliferation by TPA in PANC-1 cells was associated with an increase in the level of p21, but this was not observed in MIA PaCa-2 or BxPC-3 cells. The TPA-induced increase of p21 in PANC-1 cells was blocked by bisindolylmaleimide or rottlerin (inhibitors of protein kinase C). Studies in NCr-immunodeficient mice with well established PANC-1 tumor xenografts indicated that daily i.p. injections of TPA strongly inhibited tumor growth, increased the percentage of caspase-3-positive cells, and decreased the ratio of mitotic cells to caspase-3-positive cells in the tumors. Studies with BxPC-3 tumors in NCr mice receiving daily i.p. injections of vehicle, TPA, all-trans retinoic acid (ATRA), or a TPA/ATRA combination showed that TPA had an inhibitory effect on tumor growth, but treatment of the animals with the TPA/ATRA combination had a greater inhibitory effect on tumor growth than TPA alone. Treatment with the TPA/ATRA combination resulted in a substantially decreased ratio of the percentage of mitotic cells to the percentage of caspase-3-positive cells in the tumors compared with tumors from the vehicle-treated control animals. The inhibitory effects of TPA on tumor growth occurred at clinically achievable blood levels.

Animals↗
PubMedDate not supplied

LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas.

In this phase II study, we treated 7 patients, all males, with stage III or IV pancreatic cancer with goserelin (an LH-RH analogue). Goserelin was administered at a dose of 3.6 mg every 4 weeks. The tumour response was assessed by measuring lesions with US- or CT-scan studies, according to WHO criteria. No response was observed. The median survival was 8 months in locally unresectable tumours and 4 months in advanced disease. The accrual was actually stopped at 7 cases because there were no responses in either of our series or in those published during our study. The authors conclude that the treatment with LH-RH analogue alone cannot be recommended for further studies.

Adenocarcinoma↗
PubMed1991

[Clinical values of serum PGGT (pancreas gamma-glutamyltranstidase and PGGT/TGGT ratio in diagnosis of cancer of the head of pancreas].

737 samples of sera were determined for gamma-glutamyl transtidase Iscenzyme (PGGT). The samples were obtained from 121 healthy adults, forty pancreatic-head-cancer patients, and 576 patients with other hepato-biliary-pancreatic diseases. The positive rates of PGGT greater than 4u/l and PGGT/TGGT greater than 0.1 were 62.5% (25/40) in pancreatic-head-cancer patients, 27.02% (10/37) in patients with non-pancreatic extrahapatic-biliary-duct malignant obstructive jaundice, 1.21% (1/82) in patients with benign extrahepatic-biliary duct obstructive jaundice (biliary stones), 1.29% (1/77) in liver cancer patients, and 0% (0/380) in patients with other general surgical diseases, respectively. The positive rate of PGGT greater than 4u/L and PGGT/TGGT greater than 0.1 was significantly higher in patients with pancreatic head cancer than in patients with hepato-biliary-duct obstructive jaundice (including benign and malignant diseases) and liver cancer (x = 99.45, p less than 0.001). The study showed that the serum TGGT was mainly of hepatic origin, and its level was elevated in patients with pancreatic or/and biliary diseases, which resulted in the obstruction of the pancreatic duct and bile duct at the same time. Hence, the serum PGGT greater than 4u/L together with POGT/TGGT greater than 0.1 was mainly found in patients with pancreatic head cancer.

Adult↗